---
schema_version: "secwatch.filing_event.v1"
accession: "0001453687-24-000081"
form_type: "8-K"
ticker: "RNAC"
cik: "0001453687"
company_name: "Cartesian Therapeutics, Inc."
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T09:40:33.174741+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cartesian Q1 2024 net loss $56.8M; cash $104.8M; MG Phase 2b data on track for mid-2024

## Summary
- Net loss $56.8M ($10.50/shr) vs $21.7M ($4.24/shr) Q1 2023; loss widened on higher G&A from merger.
- Cash, equivalents, restricted cash $104.8M; expected to fund operations into 2H 2026.
- R&D expenses $9.7M (down from $18.6M) on pipeline reprioritization; G&A $9.5M (up from $5.7M) on merger costs.
- Phase 2b topline for Descartes-08 in myasthenia gravis expected mid-2024; SLE Phase 2 dosing starts Q2 2024.
- Completed 1-for-30 reverse stock split and preferred conversion; new Maryland HQ expanding manufacturing.

## SEC filing metadata
- accession: 0001453687-24-000081
- form_type: 8-K
- ticker: RNAC
- cik: 0001453687
- company_name: Cartesian Therapeutics, Inc.
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1453687/000145368724000081/0001453687-24-000081-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1453687/000145368724000081/rnac-20240508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001453687-24-000081
- JSON: https://secwatch.observer/filing/0001453687-24-000081.json
- Plain text: https://secwatch.observer/filing/0001453687-24-000081.txt

## Key facts
- Earnings Releases
  Cartesian Therapeutics, Inc. reported financial results for first quarter ended March 31, 2024.
  - Period: first quarter ended March 31, 2024
  - Result: reported results
  source text: On May 8, 2024, Cartesian Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1453687/000145368724000081/0001453687-24-000081-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.